Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NUTRAPLUS PR vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NUTRAPLUS PR   MYLAN
EQUITY SHARE DATA
    NUTRAPLUS PR
Mar-20
MYLAN
Dec-18
NUTRAPLUS PR/
MYLAN
5-Yr Chart
Click to enlarge
High Rs223,969-   
Low Rs52,185-   
Sales per share (Unadj.) Rs25.61,826.3-  
Earnings per share (Unadj.) Rs-14.049.6-  
Cash flow per share (Unadj.) Rs-12.7391.5-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs6.31,975.7-  
Shares outstanding (eoy) m34.09514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.51.7 31.6%   
Avg P/E ratio x-1.062.0 -1.6%  
P/CF ratio (eoy) x-1.17.9 -13.7%  
Price / Book Value ratio x2.11.6 138.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m4641,582,973 0.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m730-   
Avg. sales/employee Rs Th026,846.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0729.0-  
INCOME DATA
Net Sales Rs m873939,609 0.1%  
Other income Rs m10-   
Total revenues Rs m875939,609 0.1%   
Gross profit Rs m-358243,136 -0.1%  
Depreciation Rs m47175,932 0.0%   
Interest Rs m7445,192 0.2%   
Profit before tax Rs m-47822,012 -2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m0-3,502 -0.0%   
Profit after tax Rs m-47825,514 -1.9%  
Gross profit margin %-41.025.9 -158.6%  
Effective tax rate %0-15.9 0.0%   
Net profit margin %-54.82.7 -2,016.6%  
BALANCE SHEET DATA
Current assets Rs m178524,677 0.0%   
Current liabilities Rs m890382,547 0.2%   
Net working cap to sales %-81.515.1 -538.8%  
Current ratio x0.21.4 14.6%  
Inventory Days Days184 0.8%  
Debtors Days Days11,562,62593 12,390,980.8%  
Net fixed assets Rs m939182,269 0.5%   
Share capital Rs m170500 34.1%   
"Free" reserves Rs m460-   
Net worth Rs m2161,016,486 0.0%   
Long term debt Rs m21,097,114 0.0%   
Total assets Rs m1,1172,726,609 0.0%  
Interest coverage x-5.41.5 -365.5%   
Debt to equity ratio x01.1 0.9%  
Sales to assets ratio x0.80.3 227.0%   
Return on assets %-36.22.6 -1,395.1%  
Return on equity %-221.32.5 -8,815.5%  
Return on capital %-185.13.2 -5,822.6%  
Exports to sales %1.30-   
Imports to sales %0.70-   
Net fx Rs m50-   
CASH FLOW
From Operations Rs m91195,251 0.0%  
From Investments Rs m-27-100,923 0.0%  
From Financial Activity Rs m-76-90,959 0.1%  
Net Cashflow Rs m-121,618 -0.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.38 Rs / USD

Compare NUTRAPLUS PR With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NUTRAPLUS PR With: FDC  BETA DRUGS   WALPAR NUTRITIONS LTD.  GUFIC BIOSCIENCE  J.B.CHEMICALS  



Today's Market

Tata Consumer Q4 Results & Interim Dividend | M&M Finance Delays Q4 Results | Top Buzzing Stocks Today Tata Consumer Q4 Results & Interim Dividend | M&M Finance Delays Q4 Results | Top Buzzing Stocks Today(Pre-Open)

Indian share markets continued the momentum as the session progressed and ended the higher.